Kodiak Sciences: GLOW2 Readout as Key Catalyst for Tarcocimab Upside and Broader Pipeline Optionality

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on KOD stock, giving a Buy rating on January 22.

Anupam Rama has given his Buy rating due to a combination of factors centered on tarcocimab’s upcoming GLOW2 readout and Kodiak’s broader pipeline optionality. He views the GLOW2 trial in diabetic retinopathy as a key catalyst that could rehabilitate sentiment around tarcocimab and the company’s ABC platform, especially given the strong GLOW1 efficacy results on DRSS improvement and reduction in sight‑threatening events. Because GLOW2 closely follows the earlier trial design but adds a loading dose, an improved commercial formulation, and includes moderate DME patients, he sees a strong chance of replicating or improving upon prior efficacy with a cleaner cataract profile, while preserving a convenient six‑month dosing interval.

Rama also believes that a successful GLOW2 outcome would unlock a clear regulatory path for tarcocimab in both diabetic retinopathy and retinal vein occlusion, supported by prior positive BEACON data, with U.S. peak sales potential he models in the high hundreds of millions of dollars across these indications. In his valuation work, the probability‑weighted upside from a positive GLOW2 substantially outweighs the downside risk from a trial setback, with favorable skew in the share price scenario analysis. Finally, he underscores that Kodiak’s investment case is not solely dependent on tarcocimab; additional upside from KSI‑101 and optionality around KSI‑501 further support his Overweight/Buy stance on KOD shares.

In another report released on January 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $38.00 price target.